Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 24586605)

1.

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.

Meckbach D, Keim U, Richter S, Leiter U, Eigentler TK, Bauer J, Pflugfelder A, Büttner P, Garbe C, Weide B.

PLoS One. 2014 Feb 20;9(2):e89218. doi: 10.1371/journal.pone.0089218. eCollection 2014.

2.

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.

Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Hélias-Rodzewicz Z, Marin C, Peschaud F, Chagnon S, Zimmermann U, Clerici T, Emile JF.

Ann Surg Oncol. 2012 Dec;19(13):4314-21. doi: 10.1245/s10434-012-2457-5. Epub 2012 Jul 7.

PMID:
22772867
3.

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.

Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR.

Lancet Oncol. 2013 Jul;14(8):733-40. doi: 10.1016/S1470-2045(13)70237-7. Epub 2013 Jun 2.

PMID:
23735514
4.

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R.

Clin Cancer Res. 2012 Jan 15;18(2):555-67. doi: 10.1158/1078-0432.CCR-11-1491. Epub 2011 Nov 2.

5.

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.

Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD.

Eur J Cancer. 2014 Feb;50(3):611-21. doi: 10.1016/j.ejca.2013.11.002. Epub 2013 Nov 29.

PMID:
24295639
6.

Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma.

Meckbach D, Bauer J, Pflugfelder A, Meier F, Busch C, Eigentler TK, Capper D, von Deimling A, Mittelbronn M, Perner S, Ikenberg K, Hantschke M, Büttner P, Garbe C, Weide B.

PLoS One. 2014 Jan 24;9(1):e86194. doi: 10.1371/journal.pone.0086194. eCollection 2014.

7.

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA.

Cancer. 2012 Aug 15;118(16):4014-23. doi: 10.1002/cncr.26724. Epub 2011 Dec 16.

8.

Metastatic melanoma: a regional review and future directions.

Khan KH, Goody RB, Hameed H, Jalil A, Coyle VM, McAleer JJ.

Tumori. 2012 Sep-Oct;98(5):575-80. doi: 10.1700/1190.13197.

PMID:
23235751
9.

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF.

J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22.

10.

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA.

Lancet Oncol. 2014 Aug;15(9):954-65. doi: 10.1016/S1470-2045(14)70301-8. Epub 2014 Jul 15. Erratum in: Lancet Oncol. 2014 Sep;15(10):417.

PMID:
25037139
11.

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.

Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, Lambie D, Burmeister B, Thomas J, Smithers BM, Hayward NK.

Eur J Cancer. 2014 Oct;50(15):2668-76. doi: 10.1016/j.ejca.2014.06.009. Epub 2014 Jul 25.

PMID:
25070294
12.

Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.

Schlaak M, Bajah A, Podewski T, Kreuzberg N, von Bartenwerffer W, Wardelmann E, Merkelbach-Bruse S, Büttner R, Mauch C, Kurschat P.

Br J Dermatol. 2013 Apr;168(4):708-16. doi: 10.1111/bjd.12140.

PMID:
23528057
13.

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV.

Br J Cancer. 2014 Jul 15;111(2):292-9. doi: 10.1038/bjc.2014.287. Epub 2014 Jun 10.

PMID:
24918823
14.

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.

Birkeland E, Busch C, Berge EO, Geisler J, Jönsson G, Lillehaug JR, Knappskog S, Lønning PE.

Clin Exp Metastasis. 2013 Oct;30(7):867-76. doi: 10.1007/s10585-013-9587-4. Epub 2013 May 15.

15.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.

Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.

PMID:
24582505
16.

[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].

Frick S, Lischner S, Rosien F, Haacke TC, Schäfer F, Christophers E, Hauschild A.

Hautarzt. 2002 Oct;53(10):659-65. German.

PMID:
12297947
17.

Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.

Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK.

Am J Ophthalmol. 2014 Oct;158(4):831-837.e2. doi: 10.1016/j.ajo.2014.07.003. Epub 2014 Jul 15.

PMID:
25036880
18.

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.

Bucheit AD, Syklawer E, Jakob JA, Bassett RL Jr, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA.

Cancer. 2013 Nov 1;119(21):3821-9. doi: 10.1002/cncr.28306. Epub 2013 Aug 6.

19.

Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.

Marcus DM, Lowe M, Khan MK, Lawson DH, Crocker IR, Shelton JW, Melton A, Maynard N, Delman KA, Carlson GW, Rizzo M.

Am J Clin Oncol. 2014 Dec;37(6):580-4. doi: 10.1097/COC.0b013e318280d7be.

PMID:
23428955
20.

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.

Ekedahl H, Cirenajwis H, Harbst K, Carneiro A, Nielsen K, Olsson H, Lundgren L, Ingvar C, Jönsson G.

Br J Dermatol. 2013 Nov;169(5):1049-55. doi: 10.1111/bjd.12504.

PMID:
23855428
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk